In vivo protection of striatal dopaminergic system against 1-methyl-4- phenylpyridinium neurotoxicity by phenobarbital

Journal of Neuroscience Research

Volumn 49, Issue 3, 1997, Pages 301-308

  Vizuete, María Luisa ^a   Merino, Miguel ^a   Cano, Josefina ^a   Machado, Alberto ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

1 methyl 4 phenylpyridinium; Cytochrome P450; Dopaminergic neuroprotection; Phenobarbital; Rat's striatum

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; CYTOCHROME P450; NEUROPROTECTIVE AGENT; PHENOBARBITAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INTRACEREBRAL DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CATECHOLAMINES; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE; DOPAMINE AGENTS; HYPNOTICS AND SEDATIVES; IMMUNOHISTOCHEMISTRY; MALE; NEOSTRIATUM; NERVOUS SYSTEM DISEASES; PHENOBARBITAL; RATS; RATS, WISTAR; TYROSINE 3-MONOOXYGENASE;

EID: 0030791765     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19970801)49:3<301::AID-JNR5>3.0.CO;2-G     Document Type: Article

References (54)

1. Allan AM, Zhang X, Baier LD (1992): Barbiturate tolerance: Effects on GABA-operated chloride channel function. Brain Res 588:255-260.
2. Altar CA, Jakeman LB, Acwortz IN, Soriano R, Dugich-Djordjevic M (1992): Regionally restricted loss and partial recovery of nigrostriatal dopamine input following intrastiatal 6-hydroxydopamine. Neurodegeneration 1:123-133.
3. Anandatheerthavarada HK, Boyd MR, Rabindranath V (1992): Characterization of a phenobarbital-inducible cytochrome P-450, NADPH cytochrome P-450 reductase and reconstituted cytochrome P-450 mono-oxigenase system from rat brain. Evidence for constitutive presence in rat and human brain. Biochem J 288:483-488.
4. Barbeau A, Clotier T, Roy M, Plasse L, Paris S, Poirier J (1985): Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet i.i:1213-1216.
5. Bigge CF, Boxer PA (1994): Neuronal cell death and strategies for neuroprotection. In McCall J (ed): "Annual Reports in Medicinal Chemistry." San Diego, CA: Academic Press, pp 13-22.
6. 3H)norepinephrine efflux. Eur J Pharmacol 254:307-309.
7. Calabresi P, Mercuri NB, Sancesario G, Bernardi G (1993): Electrophysiology of dopamine denervated striatal neurons? Implications for Parkinson's disease. Brain 116:433-452.
8. Calne DB, Lanston JW (1983): Aetiology of Parkinson's disease. Lancet i.i:1457-1459.
9. Chan P, Langston JW, Di Monte DA (1993): MK-801 temporally prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. J Pharmacol Exp Ther 267:1515-1520.
10. Chiba Z, Trevor A, Castagnoli A (1987): Metabolism of neurotoxic tertiary amine MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578.
11. Daniell LC (1994): Effects of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membranes vesicles. Pharmacology 49:296-307.
12. Espino A, Llorens J, Calopa M, Battrons R, Rodriguez-Farre E, Ambrosio S (1995): Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion. Brain Res 669:19-25.
13. Fonne-Pfister R, Bargetzi MJ, Meyer UA (1987): MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450 db 1) catalysing debrisoquine 4 hydroxylation. Biochem Biophys Res Commun 148:1144-1150.
14. Golbe LJ (1990): The genetics of Parkinson's disease. Neurology 40:7-14.
15. González FJ (1988): The molecular biology of cytochrome P450. Pharmacol Rev 40:243-288.
16. Griffiths PD, Perry RH, Crossma AR (1994): A detailed anatomical analysis of neurotransmitter receptor in the putamen and caudate in Parkinson's disease and Alzheimer disease. Neurosci lett 169:68-72.
17. Hodgson AV, White TB, White JW, Strobel HW (1993): Expression analysis of the mixed function oxidase system in rat brain by the polimerase chain reaction. Mol Cell Biochem 120:171-179.
18. Holland KD, McKean AC, Canney DJ, Govey DF, Ferrendelli JA (1992): Relative anticonvulsivant effects of GABAmimetic and GABA modulatory agents. Epilepsia 33:981-986.
19. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 49:617-621.
20. Jasso-López D, Tapia R (1995): Neurotoxic effect of intranigral injection of 1-methyl-4-phenylpyridinium on GABA containing neurons and its relation to circling behavior. J Neurochem 64:794-801.
21. Javitch JA, Damato RJ, Strittmatter SM, Snyder SH (1994): Parkinson-ism-inducing neurotoxins, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains toxicity. Proc Natl Acad Sci USA 82:2173-2177.
22. Jiménez-Jiménez FJ, Tabernero C, Mena MA, García de Yébenes J, Casarejos MJ, Pardo B, García Agúndez JA, Benítez J, Martínez A, López García-Asenjo JA (1991): Acute effects of 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J Neurochem 57:81-87.
23. Johnson WG (1991): Genetic susceptibility to Parkinson's disease. Neurology 41:82-87.
24. Karuzina II, Archakov AI (1994): Hydrogen peroxide-mediated inactivation of microsomal cytochrome P450 during monooxigenase reactions. Free Rad Biol Med 17:557-563.
25. Lapchack PA, Hefti F (1992): BDNF and NGF in lesioned rats: Effects on cholinergic function and weight gain. NeuroReport 3:405-408.
26. Lin SZ, Chiou TL, Chiang YH, Song WS (1994): Combined treatment with nicardipine, phenobarbital and methilprednisolone ameliorates vasogenic brain edema. Acta Neurochir Suppl 60:528-530.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951): Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
28. Lui Y, Peter D, Roghani A, Schldiner S, Privé GG, Eisenberg D, Brecha N, Edwards RH (1992): A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:533-551.
29. Macdonald RL, McLean MJ (1986): Anticonvulsant drugs: Mechanism of action. In Delgado-Escueta AV, Ward AA Jr, Woodbury DM, Porter RJ (eds): "Advances in Neurology." New York: Raven Press, vol 44, pp 713-736.
30. Mattson MP (1992): Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol 27:29-49.
31. Melamed E, Martinovits G, Pikarsky E, Rosenthal J, Uzzan A (1986): Dyphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. Eur J Pharmacol 128:255-257.
32. Nebert DW, Nelson DR, Coon MJ, Estrabook RW, Feyereisen R, Fujii-Kuriyama Y, González FJ, Guengerich FP, Gunsalus IC, Jonhson EF, Loper JC, Sato R, Waterman MR, Waxman DJ (1991): The P450 superfamily: Update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 10:1-14.
33. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW (1993): The P450 superfamily: Update on new sequences, gene mapping, accession number, early trivial names of enzymes and nomenclature. DNA Cell Biol 12:1-51.
34. Olanow CW (1990): Oxidation reactions in Parkinson's disease. Neurology 40:32-39.
35. Olney JW (1989): Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26:505-525.
36. Paxinos G, Watson C (1986): "The Rat Brain in Stereotaxic Coordinates." Second Edition. London: Academic Press Inc.
37. Ramsay RR, Krueger MJ, Youngster SK, Gluck MR, Casida JE, Singer TP (1991): Interaction of 1-Methyl-4-phenylpyridinium ion (MPP+) and its analogs with rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 56:1184-1190.
38. 3H]tyrosine by charcoal. Life Sci 39:2185-2189.
39. Renaud JP, Boucher JL, Vadon S, Delaforge M, Mansui D (1993): Particular ability of liver P450s3A to catalize the oxidation of N omega-hydroxyarginine to citruline and nitrogen oxides and occurence in no synthases of a sequence very similar to the heme-binding sequence in P450s. Biochem Biophys Res Commun 193:53-60.
40. Schoemaker H, Nikolson VJ (1983): Dopamine uptake by rat striatal synaptosomes: time-and temperature-dependent decay and protection by dithiothreitol and dopamine. J Neurochem 40:922-928.
41. Schwartz RD, Yu X, Katzman MR, Hayden-Hixson DM and Perry JM (1995): Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. J Neurosci 15:529-539.
42. Shina BK, Singh Y, Krisnha G (1986): Formation of Superoxide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion MPP+: Reductive activation by NADPH cytochrome P-450 reductase. Biochem Biophys Res Commun 135:283-288.
43. Shuaib A, Ijaz S, Hasan S, Kalra J (1992): Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in transient forebrain ischemia. Brain Res 590:13-17.
44. Smith CAD, Cough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Shapira AHV, Willians AC, Spurr NK, Wolf CR (1992): Debrisoquine hydroxilase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377.
45. Sofia RD, Gordon R, Geis M, Diamantis W (1994): Comparative effects of felbamate and other compounds on N-melhyl-Daspartic acid-induced convulsions and lethality in mice. Pharmacol Res 29:139-144.
46. Sriram K, Karnine SP, Ravindranath V (1995): Protection and potentiation of 1-Methyl-4-Phenylpyridinium-induced toxicity P450 inhibitors an inducer may be due to the altered uptake of the toxin. J Neurochem 64:1203-1208.
47. Srivastasva R, Brouilleyt E, Beal MF, Storey E, Hyman BT (1993): Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat prior decortication of MK-801 treatment: A stereological estimate of neuronal loss. Neurobiol Aging 14:295-301.
48. Strobel HW, Cattaneo E, Adesnik M, Maggi A (1989): Brain cytochrome P450 are responsive to phenobarbital and tricicles amines. Pharmacol Res 21:169-175.
49. Tohgi H, Abe T, Hashiguchi K, Takahasashi S, Nozaki Y, Kikuchi T (1991): A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration. Neurosci Lett 126:155-158.
50. Turski L, Bressler K, Rettig KJ, Löschmann PA, Wachtel H (1991): Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonist. Nature 349:414-418.
51. Turski L, Stephens DN (1992): Excitatory amino acid antagonist protect mice againts MPP+ seizures. Synapse 10:120-125.
52. Volpi R, Scaglioni A, Marcato A, Caffarra P, Rossi G, Caffarri G, Delsignore R, Chiodera P, Coiro V (1991): Failure of the gamma-aminobutiric acid (GABA) derivate, baclofen, to stimulate growth hormone secretion in Parkinson's disease. J Neural Transm Park Dis Dement Sect 3:259-264.
53. Wu RM, Chiueh CC, Murphy DL (1993): Protection of substantia nigra A9 neurons by deprenyl againts MPP+ induced oxidative injury. Soc Neurochem Abstr 19:402.
54. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GV (1992): MK-801 prevents MPTP-induced parkinsonism in primates. J Neurochem 59:733-739.